![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TTL |
Gene summary for TTL |
![]() |
Gene information | Species | Human | Gene symbol | TTL | Gene ID | 150465 |
Gene name | tubulin tyrosine ligase | |
Gene Alias | TTL | |
Cytomap | 2q14.1 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q8NG68 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
150465 | TTL | HCC1_Meng | Human | Liver | HCC | 2.30e-18 | 1.76e-02 | 0.0246 |
150465 | TTL | HCC2 | Human | Liver | HCC | 9.58e-20 | 3.89e+00 | 0.5341 |
150465 | TTL | Pt14.a | Human | Liver | HCC | 2.24e-03 | 2.59e-01 | 0.0169 |
150465 | TTL | S014 | Human | Liver | HCC | 1.02e-03 | 2.53e-01 | 0.2254 |
150465 | TTL | S016 | Human | Liver | HCC | 1.25e-02 | 1.97e-01 | 0.2243 |
150465 | TTL | S028 | Human | Liver | HCC | 1.53e-16 | 5.89e-01 | 0.2503 |
150465 | TTL | S029 | Human | Liver | HCC | 2.40e-10 | 5.72e-01 | 0.2581 |
150465 | TTL | C04 | Human | Oral cavity | OSCC | 1.01e-08 | 6.21e-01 | 0.2633 |
150465 | TTL | C21 | Human | Oral cavity | OSCC | 4.49e-08 | 3.48e-01 | 0.2678 |
150465 | TTL | C30 | Human | Oral cavity | OSCC | 6.89e-11 | 5.60e-01 | 0.3055 |
150465 | TTL | C38 | Human | Oral cavity | OSCC | 8.98e-05 | 5.37e-01 | 0.172 |
150465 | TTL | C46 | Human | Oral cavity | OSCC | 2.38e-02 | 1.46e-01 | 0.1673 |
150465 | TTL | C51 | Human | Oral cavity | OSCC | 8.78e-04 | 2.58e-01 | 0.2674 |
150465 | TTL | C09 | Human | Oral cavity | OSCC | 3.48e-02 | 9.74e-02 | 0.1431 |
150465 | TTL | SYSMH1 | Human | Oral cavity | OSCC | 5.30e-08 | 2.88e-01 | 0.1127 |
150465 | TTL | SYSMH2 | Human | Oral cavity | OSCC | 3.78e-09 | 3.36e-01 | 0.2326 |
150465 | TTL | SYSMH3 | Human | Oral cavity | OSCC | 3.60e-23 | 5.98e-01 | 0.2442 |
150465 | TTL | male-WTA | Human | Thyroid | PTC | 2.21e-14 | 1.64e-01 | 0.1037 |
150465 | TTL | PTC01 | Human | Thyroid | PTC | 1.95e-02 | 3.73e-02 | 0.1899 |
150465 | TTL | PTC04 | Human | Thyroid | PTC | 1.89e-05 | 1.61e-01 | 0.1927 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00450881 | Liver | HCC | regulation of innate immune response | 113/7958 | 218/18723 | 3.27e-03 | 1.50e-02 | 113 |
GO:004348921 | Liver | HCC | RNA stabilization | 39/7958 | 65/18723 | 3.31e-03 | 1.51e-02 | 39 |
GO:00458241 | Liver | HCC | negative regulation of innate immune response | 42/7958 | 71/18723 | 3.41e-03 | 1.55e-02 | 42 |
GO:00083614 | Liver | HCC | regulation of cell size | 95/7958 | 181/18723 | 4.15e-03 | 1.81e-02 | 95 |
GO:0050777 | Liver | HCC | negative regulation of immune response | 101/7958 | 194/18723 | 4.40e-03 | 1.90e-02 | 101 |
GO:0043687 | Liver | HCC | post-translational protein modification | 24/7958 | 37/18723 | 5.03e-03 | 2.11e-02 | 24 |
GO:190237311 | Liver | HCC | negative regulation of mRNA catabolic process | 37/7958 | 63/18723 | 6.82e-03 | 2.73e-02 | 37 |
GO:0080009 | Liver | HCC | mRNA methylation | 12/7958 | 16/18723 | 8.74e-03 | 3.40e-02 | 12 |
GO:004825511 | Liver | HCC | mRNA stabilization | 33/7958 | 56/18723 | 9.64e-03 | 3.63e-02 | 33 |
GO:0016556 | Liver | HCC | mRNA modification | 18/7958 | 27/18723 | 9.75e-03 | 3.66e-02 | 18 |
GO:00305164 | Liver | HCC | regulation of axon extension | 52/7958 | 95/18723 | 1.07e-02 | 3.97e-02 | 52 |
GO:00098968 | Lung | IAC | positive regulation of catabolic process | 114/2061 | 492/18723 | 4.93e-15 | 1.25e-11 | 114 |
GO:00434848 | Lung | IAC | regulation of RNA splicing | 49/2061 | 148/18723 | 4.76e-13 | 7.06e-10 | 49 |
GO:00313318 | Lung | IAC | positive regulation of cellular catabolic process | 98/2061 | 427/18723 | 7.79e-13 | 9.25e-10 | 98 |
GO:19033117 | Lung | IAC | regulation of mRNA metabolic process | 71/2061 | 288/18723 | 3.76e-11 | 1.24e-08 | 71 |
GO:00480248 | Lung | IAC | regulation of mRNA splicing, via spliceosome | 34/2061 | 101/18723 | 1.05e-09 | 1.95e-07 | 34 |
GO:00506847 | Lung | IAC | regulation of mRNA processing | 41/2061 | 137/18723 | 1.23e-09 | 2.15e-07 | 41 |
GO:00098958 | Lung | IAC | negative regulation of catabolic process | 66/2061 | 320/18723 | 3.26e-07 | 2.48e-05 | 66 |
GO:00313308 | Lung | IAC | negative regulation of cellular catabolic process | 57/2061 | 262/18723 | 3.31e-07 | 2.49e-05 | 57 |
GO:00064178 | Lung | IAC | regulation of translation | 86/2061 | 468/18723 | 1.16e-06 | 6.18e-05 | 86 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TTL | SNV | Missense_Mutation | c.971N>G | p.Glu324Gly | p.E324G | Q8NG68 | protein_coding | tolerated(0.16) | benign(0.026) | TCGA-B6-A0IC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | novel | c.131G>T | p.Arg44Met | p.R44M | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.909) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TTL | SNV | Missense_Mutation | novel | c.968A>G | p.Glu323Gly | p.E323G | Q8NG68 | protein_coding | deleterious(0.04) | benign(0.093) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TTL | SNV | Missense_Mutation | rs746535633 | c.279N>T | p.Trp93Cys | p.W93C | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
TTL | SNV | Missense_Mutation | c.217N>T | p.Arg73Cys | p.R73C | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | c.414G>T | p.Lys138Asn | p.K138N | Q8NG68 | protein_coding | tolerated(0.13) | benign(0.163) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | novel | c.661N>A | p.Leu221Ile | p.L221I | Q8NG68 | protein_coding | deleterious(0.03) | possibly_damaging(0.883) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TTL | SNV | Missense_Mutation | c.170N>T | p.Gly57Val | p.G57V | Q8NG68 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | c.679C>A | p.Pro227Thr | p.P227T | Q8NG68 | protein_coding | deleterious(0.02) | possibly_damaging(0.575) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TTL | SNV | Missense_Mutation | rs780073175 | c.218N>A | p.Arg73His | p.R73H | Q8NG68 | protein_coding | deleterious(0.02) | probably_damaging(0.925) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |